Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.

Authors

Antonio D'Alessio

Antonio D'Alessio

Imperial College, London, United Kingdom

Antonio D'Alessio , Bernardo Stefanini , Julia Blanter , Benjamin Adegbite , Claudia A.M. Fulgenzi , Ciro Celsa , Giulia F Manfredi , Madhava Pai , Robert D. Goldin , Daniel Shu , Yung-Yeh Su , Marina Baretti , Robert A. Anders , Mark Yarchoan , Chiun Hsu , Thomas Urban Marron , David James Pinato

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 506)

DOI

10.1200/JCO.2024.42.3_suppl.506

Abstract #

506

Poster Bd #

D13

Abstract Disclosures